Chimeric antigen receptor -T cell therapy (CAR-T cell therapy) is a cancer treatment that shows remarkable clinical responses in hematologic malignancies. The FDA first approved CAR-T for adult commercial use in October of 2017. It was approved to treat two types of blood cancers: aggressive B cell non-Hodgkin lymphoma in adults and B cell acute leukemia in children and young adults up to age 25. CAR-T cell therapy is reserved for patients whose disease has not responded to other cancer treatments.
When Mayo Clinic began to plan for its first commercial CAR-T treatment launch they leaned on Management Engineering and Consulting staff to help understand the scope of the effort, design the process, and guide the implementation. In this effort Emma Erickson and Dan Gronseth were instrumental in the design and implementation of the process. Join Dan Gronseth, Senior Principle Health Systems Engineer, Emma Erickson, Senior Health Systems Engineer and host Tony Chihak as they discuss their work on this groundbreaking treatment.
Watch Now! Episode 3